EGFR and chordoma: N-(3-ethynylphenyl)-6,7-difluoroquinazolin-4-amine (6) displayed weaker activity against EGFR in A431 cells (IC50 = 12 μM), and no potency in the four additional patient-derived chordoma cell lines or WS1 control (IC50 = > 100 μM).